- Home
- ATAT vs AXSM Comparison
ATAT vs AXSM Comparison
Compare ATAT & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAT
- AXSM
- Stock Information
- Founded
- ATAT 2013
- AXSM 2012
- Country
- ATAT China
- AXSM United States
- Employees
- ATAT N/A
- AXSM N/A
- Industry
- ATAT Hotels/Resorts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- ATAT Consumer Discretionary
- AXSM Health Care
- Exchange
- ATAT Nasdaq
- AXSM Nasdaq
- Market Cap
- ATAT 4.2B
- AXSM 5.1B
- IPO Year
- ATAT 2022
- AXSM 2015
- Fundamental
- Price
- ATAT $35.69
- AXSM $100.83
- Analyst Decision
- ATAT Strong Buy
- AXSM Strong Buy
- Analyst Count
- ATAT 2
- AXSM 17
- Target Price
- ATAT $37.40
- AXSM $171.65
- AVG Volume (30 Days)
- ATAT 1.5M
- AXSM 626.0K
- Earning Date
- ATAT 08-28-2025
- AXSM 08-04-2025
- Dividend Yield
- ATAT 1.26%
- AXSM N/A
- EPS Growth
- ATAT 28.10
- AXSM N/A
- EPS
- ATAT 1.25
- AXSM N/A
- Revenue
- ATAT $1,059,112,934.00
- AXSM $432,157,000.00
- Revenue This Year
- ATAT $31.42
- AXSM $62.57
- Revenue Next Year
- ATAT $21.88
- AXSM $59.96
- P/E Ratio
- ATAT $28.59
- AXSM N/A
- Revenue Growth
- ATAT 43.38
- AXSM 72.16
- 52 Week Low
- ATAT $15.22
- AXSM $72.21
- 52 Week High
- ATAT $37.46
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- ATAT 61.21
- AXSM 39.48
- Support Level
- ATAT $35.26
- AXSM $101.36
- Resistance Level
- ATAT $37.24
- AXSM $106.99
- Average True Range (ATR)
- ATAT 1.17
- AXSM 4.12
- MACD
- ATAT -0.13
- AXSM -0.87
- Stochastic Oscillator
- ATAT 43.09
- AXSM 0.36
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.